Critical Comparison: Anthera Pharmaceuticals (ANTH) vs. Rocket Pharmaceuticals (RCKT)

Anthera Pharmaceuticals (NASDAQ: ANTH) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares Anthera Pharmaceuticals and Rocket Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anthera Pharmaceuticals $140,000.00 126.63 -$55.52 million ($5.42) -0.24
Rocket Pharmaceuticals N/A N/A -$42.85 million ($6.12) -2.07

Rocket Pharmaceuticals has lower revenue, but higher earnings than Anthera Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Anthera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares Anthera Pharmaceuticals and Rocket Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anthera Pharmaceuticals N/A -1,497.08% -224.18%
Rocket Pharmaceuticals N/A -61.38% -32.46%

Insider & Institutional Ownership

16.1% of Anthera Pharmaceuticals shares are owned by institutional investors. 2.1% of Anthera Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Anthera Pharmaceuticals and Rocket Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anthera Pharmaceuticals 0 1 1 0 2.50
Rocket Pharmaceuticals 0 2 0 0 2.00

Anthera Pharmaceuticals presently has a consensus price target of $2.38, suggesting a potential upside of 85.55%. Rocket Pharmaceuticals has a consensus price target of $2.50, suggesting a potential downside of 80.24%. Given Anthera Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Anthera Pharmaceuticals is more favorable than Rocket Pharmaceuticals.

Risk and Volatility

Anthera Pharmaceuticals has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 3.16, suggesting that its stock price is 216% more volatile than the S&P 500.


Anthera Pharmaceuticals beats Rocket Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply